Renovaro INC

Lunai Bioworks CEO David Weinstein's letter to shareholders highlights advancements in its AI-driven biodefense platform, precision neurology pipeline, and ongoing litigation against alleged market manipulation.

Lunai Bioworks, Inc. has received confirmation from Nasdaq that it has regained compliance with the minimum bid price rule, subject to a one-year monitoring period.

Lunai Bioworks, Inc. is implementing a 1-for-8 reverse stock split to increase its share price and comply with Nasdaq listing requirements.

Lunai Bioworks, Inc. announced that its stockholders approved a reverse stock split proposal at a special meeting held on May 8, 2026.

Lunai Bioworks discloses an additional Nasdaq staff determination regarding non-compliance with market value requirements while pursuing a reverse stock split.

Lunai Bioworks acquired a multi-jurisdictional patent portfolio from Oncotelic and Pelerin Therapeutics in exchange for $20 million in Series B Convertible Preferred Stock.

Lunai Bioworks reports Q3 2026 financial results, highlighting a net loss of $2.57 million and ongoing efforts to secure capital for its AI-driven precision medicine platform.

Lunai Bioworks Inc. reported a net income of $2.82 million for the quarter ended September 30, 2025, a significant improvement from a prior-year loss, driven by one-time gains and reduced operating expenses, despite ongoing legal challenges and a 'going concern' warning.

Renovaro Inc.'s Q3 2025 results reveal a net income of $189,176, a significant improvement from the prior year, but the company acknowledges substantial doubt about its ability to continue as a going concern.

Renovaro Inc.'s Q2 2025 financial results reveal a substantial increase in net loss primarily due to a significant goodwill impairment charge.

Renovaro Inc. is restating its Q1 2025 financial statements due to a material misstatement related to the exercising of certain warrants, and reports a significant goodwill impairment charge.

Renovaro Inc. restated its Q3 2024 financial statements due to material misstatements related to warrant exercises and an impairment charge, impacting previously reported assets, losses, and earnings per share.

Lunai Bioworks Inc. reported a significant increase in net loss for fiscal year 2025, alongside a subsidiary's bankruptcy and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.

Renovaro Inc. restated its 2024 financial statements due to a material misstatement related to the accounting for warrant exercises, impacting the fair value of contingent consideration.

Renovaro Inc. has filed an amendment to its annual report to include required information on directors, executive compensation, and a new clawback policy.

Renovaro Inc.'s 10-K filing details a year of significant financial losses, strategic realignment towards AI-driven diagnostics, and ongoing efforts to secure additional funding.

Director William Anderson Wittekind reports a transfer of 350,000 shares and adjustments to his beneficial ownership in Renovaro Inc.

Renovaro Inc. and Predictive Oncology Inc. amend their letter of intent, extending the acquisition deadline to March 31, 2025, and involving further share purchases by Renovaro.

Director Maurice van Tilburg reports acquisition of Renovaro Inc. shares and options.

Nathen Fuentes, CFO of Renovaro Inc., reports the acquisition of options to purchase 250,000 shares of common stock.

Mark Anthony Collins, a director of Renovaro Inc., acquired options to purchase 120,968 shares of common stock on November 4, 2024.

Director Douglas W. Calder reports acquisition of options to purchase 120,968 shares of Renovaro Inc. common stock.

Lunai Bioworks, Inc. is holding a special meeting on May 4, 2026, to seek stockholder approval for a reverse stock split aimed at maintaining its Nasdaq listing.

Lunai Bioworks, Inc. will hold its 2025 Annual Meeting to vote on key governance matters, including an expanded equity incentive plan, as the company navigates significant net losses and recent dilutive debt restructuring.

Renovaro Inc. is seeking shareholder approval for a reverse stock split ranging from 1-for-3 to 1-for-10 to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

A Delaware court dismissed key claims against K&L Gates LLP and Clayton Parker in a lawsuit brought by William Anderson Wittekind's entity, Weird Science LLC, regarding Lunai Bioworks Inc. shares.

William Anderson Wittekind's beneficial ownership in Lunai Bioworks Inc. decreased to 6.8% following the Issuer's recent share sale.

A Delaware Court of Chancery dismissed fraud, conspiracy, and unjust enrichment claims against William Anderson Wittekind and Weird Science LLC, key shareholders of Lunai Bioworks Inc.

William Anderson Wittekind's beneficial ownership in Renovaro Inc. has decreased from 10.4% to 8.0% due to the impending issuance of 53.6 million new shares from convertible note conversions.

William Anderson Wittekind's beneficial ownership in Renovaro Inc. decreased to 10.4% from 11.4% due to the issuance of 15 million shares for the Biosymetrics acquisition, while multiple complex legal disputes continue.

Hans Christian Hansen and associated entities report beneficial ownership of 9.4% of Lunai Bioworks Inc. common stock.

Laksya Ventures Inc. and Neil Persh jointly reported a 9.6% beneficial ownership stake in Lunai Bioworks Inc., primarily through convertible note conversions.